Medicago and GSK announced approval by Health Canada of COVIFENZ, an adjuvanted plant-based COVID-19 vaccine
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 23, 2022, Sanofi and GSK today announce that they intend to submit data from both their…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovidï¾™ COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
On Feb. 18, 2022, the WHO announced the first six countries that will receive the technology needed to…
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovidï¾™ COVID-19 Vaccine (Recombinant protein,…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…
On Feb. 15, 2022, Pfizer announced that the European Medicines Agency had approved the companyï¾’s 20-valent pneumococcal conjugate…
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
On Feb. 10, 2022, Scripps Research announced that the COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the…
On Feb. 9, 2022, the Indiana Department of Health confirmed that a case of H5N1 highly pathogenic avian…
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
On Jan. 28, 2022, the WHO announced that COVID-19 information had reached 1,292,209 people through Viamoï¾’s 3-2-1 Platform…
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
On Jan. 24, 2022, the University of Oxford announced that a third booster dose of either the ChAdOx1…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 16, 2022, the WHO announced that it had shipped 1.1 million COVID-19 vaccines to Rwanda on…